Characteristics of 171 patients with AL amyloidosis
| Variable . | n (%) . | Median (range) . |
|---|---|---|
| Age, y | — | 64 (38-84) |
| Male sex | 100 (58) | — |
| Kidney involvement | 127 (74) | — |
| Heart involvement (mLVW thickness > 12 mm) | 119 (70) | — |
| Peripheral nervous system involvement | 40 (23) | — |
| Liver involvement | 30 (17) | — |
| > 1 organ involved | 141 (82) | — |
| iFLC > 125 mg/L | 89 (52) | — |
| NYHA class > 2 | 64 (37) | — |
| EF < 55% | 52 (30) | — |
| eGFR, mL/min per 1.73 m2 | — | 68 (9-136) |
| eGFR < 60 mL/min per 1.73 m2 | 62 (36) | — |
| hs-cTnT, ng/L | — | 31 (3-420) |
| hs-cTnT > 14 ng/L | 121 (71) | — |
| hs-cTnT > 77 ng/L | 39 (23) | — |
| cTnI, ng/L | — | 40 (0-85) |
| cTnI > 40 ng/L | 79 (46) | — |
| cTnI > 70 ng/L | 40 (23) | — |
| cTnI > 100 ng/L | 31 (18) | — |
| NT-proBNP, ng/L | — | 2591 (25-35 563) |
| NT-proBNP > 332 ng/L | 134 (78) | — |
| NT-proBNP > 2736 ng/L | 64 (37) | — |
| Mayo Clinic stage I (NT-proBNP < 332 ng/L and cTnI < 100 ng/L) | 37 (22) | — |
| Mayo Clinic stage II (NT-proBNP ≥ 332 ng/L or cTnI ≥ 100 ng/L) | 103 (60) | — |
| Mayo Clinic stage III (NT-proBNP ≥ 332 ng/L and cTnI ≥ 100 ng/L) | 31 (18) | — |
| Variable . | n (%) . | Median (range) . |
|---|---|---|
| Age, y | — | 64 (38-84) |
| Male sex | 100 (58) | — |
| Kidney involvement | 127 (74) | — |
| Heart involvement (mLVW thickness > 12 mm) | 119 (70) | — |
| Peripheral nervous system involvement | 40 (23) | — |
| Liver involvement | 30 (17) | — |
| > 1 organ involved | 141 (82) | — |
| iFLC > 125 mg/L | 89 (52) | — |
| NYHA class > 2 | 64 (37) | — |
| EF < 55% | 52 (30) | — |
| eGFR, mL/min per 1.73 m2 | — | 68 (9-136) |
| eGFR < 60 mL/min per 1.73 m2 | 62 (36) | — |
| hs-cTnT, ng/L | — | 31 (3-420) |
| hs-cTnT > 14 ng/L | 121 (71) | — |
| hs-cTnT > 77 ng/L | 39 (23) | — |
| cTnI, ng/L | — | 40 (0-85) |
| cTnI > 40 ng/L | 79 (46) | — |
| cTnI > 70 ng/L | 40 (23) | — |
| cTnI > 100 ng/L | 31 (18) | — |
| NT-proBNP, ng/L | — | 2591 (25-35 563) |
| NT-proBNP > 332 ng/L | 134 (78) | — |
| NT-proBNP > 2736 ng/L | 64 (37) | — |
| Mayo Clinic stage I (NT-proBNP < 332 ng/L and cTnI < 100 ng/L) | 37 (22) | — |
| Mayo Clinic stage II (NT-proBNP ≥ 332 ng/L or cTnI ≥ 100 ng/L) | 103 (60) | — |
| Mayo Clinic stage III (NT-proBNP ≥ 332 ng/L and cTnI ≥ 100 ng/L) | 31 (18) | — |
— indicates not applicable; NYHA, New York Heart Association; and EF, ejection fraction.